Armaviskon Plus solution for intra-systemic injection. 1.5%, 2ml # 1 syringe

• To increase the mobility of the joint and eliminate pain caused by degenerative-dystrophic or post-traumatic changes in the joints;

• For rehabilitation after arthroscopy;

• For the treatment of patients with increased physical activity and regularly loading the affected joint.

Moderate pain, swelling, fever and redness in the injection area, and an increase in the exudate content in the joint cavity are possible.

The above symptoms are transient and usually disappear after 24 hours. If these symptoms occur, it is recommended to relieve the affected joint and apply ice. Allergic reactions are extremely rare.

Composition for 1 ml:

sodium hyaluronate - 13.5-16.5 mg / ml (1.5%),

sodium chloride - 8.50 mg / ml,

sodium hydrogen phosphate dihydrate - 0.22 mg / ml,

sodium dihydrogen phosphate dihydrate - 0.044 mg / ml,

water for injection - up to 1 ml.

• hypersensitivity to the components of the product;

• the presence of infection or damage to the skin in the area of ??injection;

• acute synovitis;

• pregnancy and lactation;

• children under 18 years of age (due to lack of clinical data).

pharmachologic effect

Applications - orthopedics, rheumatology, traumatology, surgery, sports medicine.

Armaviskon Plus is a joint synovial fluid protector. It is used against the background of degenerative changes in the surface of synovial cartilage to improve joint mobility, reduce pain, reduce inflammatory reactions and restore cartilage homeostasis.

Properties and efficiency:

The tool has an analgesic, corrective effect on the metabolism of bone and cartilage tissue.

Armaviskon Plus is a sterile, viscous solution of sodium salt of hyaluronic acid (sodium hyaluronate) of high purity, high molecular weight.

Hyaluronic acid, an essential component of the extracellular matrix, is present in high concentrations in cartilage and synovial fluid. Hyaluronic acid provides viscosity and elasticity to the synovial fluid and is essential for the formation of cartilage. In osteoarthritis, there is a deficiency and qualitative changes in hyaluronic acid in the synovial fluid and cartilage. Intra-articular administration of hyaluronic acid leads to an improvement in the functional state of the joint.

When using Armaviskon Plus in osteoarthritis of the knee joint, there is an improvement in the clinical course of osteoarthritis up to six months from the date of application, an anti-inflammatory and analgesic effect is observed due to the replenishment of the volume and restoration of the viscosity and elasticity of the synovial fluid, which fills the joint cavity and acts as an intra-articular lubricant. It prevents friction of the articular surfaces, which helps eliminate pain and inflammation. And also protects against premature wear and destruction of hyaline cartilage, provides mobility, has shock-absorbing ability (dampens external shocks, protecting the components of the joint from damage).

A solution of sodium hyaluronate is distributed locally in the joint cavity, where it undergoes local transformations, providing a lubricating effect. Removal or replacement of the agent is not applicable, since it is inseparably mixed with the synovial fluid of the joint.

Side effects

Moderate pain, swelling, fever and redness in the injection area, and an increase in the exudate content in the joint cavity are possible.

The above symptoms are transient and usually disappear after 24 hours. If these symptoms occur, it is recommended to relieve the affected joint and apply ice. Allergic reactions are extremely rare.

Interaction

Armaviskon Plus should not be administered concurrently with other intra-articular injections, due to the lack of significant experience.

Disinfectants containing quaternary ammonium compounds should not be used as hyaluronic acid precipitates in the presence of these substances.